A University of Chicago Consortium Phase II Trial of SB-715992 in Advanced Renal Cell Cancer

BACKGROUND: Advanced renal cell cancer (RCC) continues to have a poor overall prognosis despite new FDA-approved therapies. Although taxane-based therapies are generally ineffective in RCC, research into the role of the von Hippel-Lindau protein has shown an association with microtubule dynamics. Mi...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Lee, Richard T., Beekman, Kathleen E., Hussain, Maha, Davis, Nancy B., Clark, Joseph I., Thomas, Sachdev P., Nichols, Katherine F., Stadler, Walter M.
Format: Artigo
Sprache:Inglês
Veröffentlicht: 2008
Schlagworte:
Article
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC2704464/
https://ncbi.nlm.nih.gov/pubmed/18501078
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge